Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 32Gastrointestinal 25Thoracic 16Head & Neck 9Tumor-Agnostic 7Sarcoma 6Other solid neoplasm 5Dermatologic 5Breast 5Genitourinary 3CNS 3Plasma cell 2Endocrine 2Lymphoid 1

Conditions

Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
dostarlimab × Endocrine × Clear all
NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
48 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06333314 2025-12-02

Pan-MSI-ACSE

UNICANCER

Phase 2 Recruiting
120 enrolled
EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡